Key facts
- This page summarizes TAKEDA PHARMACEUTICAL CO LTD's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 26 Oct 2021, 20:31.
TAKEDA PHARMACEUTICAL CO LTD - 26 Oct 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- XLO
- Reported as of
- 26 Oct 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Oct 2021, 20:31:56 UTC
- Prior SEC filing
- 21 Oct 2021
- Next SEC filing
- 08 Nov 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
TAKEDA PHARMACEUTICAL CO LTD filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 26 Oct 2021.
Change
- Previous filing in this sequence was filed on 21 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XLO
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,475,121
- Change %
- Price
- Shares after
- 1,475,121
- Date
- 26 Oct 2021
- Ownership
- See explanation
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
XLO
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,248,180
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 26 Oct 2021
- Ownership
- See explanation
- Underlying class
- Common Stock
- Underlying amount
- 1,248,180
- Exercise price
- Footnotes
- F1, F2, F3
XLO
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -226,941
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 26 Oct 2021
- Ownership
- See explanation
- Underlying class
- Common Stock
- Underlying amount
- 226,941
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
TAKEDA PHARMACEUTICAL CO LTD is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuers Common Stock on a one-for-one basis immediately prior to the completion of the Issuers initial public offering for no additional consideration. The Preferred Stock had no expiration date.
Footnote F2
This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Takeda Ventures, Inc.
Footnote F3
The reportable securities are owned directly by Takeda Ventures, Inc. Takeda Pharmaceutical Company Limiteds beneficial ownership of these securities is comprised of the reportable securities owned by Takeda Ventures, Inc. Takeda Ventures, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.